Virdalis

Executive Summary

Virdalis is a Singapore-based gene therapy company focused on developing durable, potentially one-time curative treatments for rare monogenic disorders. Founded in 2020, the company operates in the preclinical stage and employs a viral vector delivery platform to address high-unmet-need genetic diseases. Despite its early stage, Virdalis benefits from Singapore's supportive biotech ecosystem and a lean operational model. The company has not disclosed total funding or valuation, indicating a need for capital to advance its pipeline toward clinical trials. Key near-term milestones include completion of preclinical proof-of-concept studies, candidate selection for lead programs, and potential IND-enabling activities. Given the competitive gene therapy landscape and capital-intensive nature of the field, Virdalis faces significant execution risk. However, its focus on rare diseases with clear genetic targets may offer a faster path to clinical validation. Success will depend on securing partnerships or additional funding to bridge the gap to first-in-human studies.

Upcoming Catalysts (preview)

• Q4 2026Lead Program Preclinical Data Release60% success
• Q2 2027Series A Funding Round Close50% success
• Q4 2027IND Filing for Lead Asset30% success